OBJECTIVE: To determine the persistence of bactericidal antibody titres following immunisation with serogroup C meningococcal glycoconjugate vaccine at age 6-15 years in order to examine changes in persistence of antibodies with age. DESIGN: Observational study. SETTING: Secondary and tertiary educational institutions in the United Kingdom. PARTICIPANTS: Healthy adolescents aged 11-20 years previously immunised between 6 and 15 years of age with one of the three serogroup C meningococcal vaccines. INTERVENTION: Serum obtained by venepuncture. MAIN OUTCOME MEASURES: Percentage of participants with (rabbit complement) serum bactericidal antibody titres of at least 1:8; geometric mean titres of serogroup C meningococcal serum bactericidal antibody. RESULTS: Five years after immunisation, 84.1% (95% confidence interval 81.6% to 86.3%) of 987 participants had a bactericidal antibody titre of at least 1:8. Geometric mean titres of bactericidal antibody were significantly lower in 11-13 year olds (147, 95% confidence interval 115 to 188) than in 14-16 year olds (300, 237 to 380) and 17-20 year olds (360, 252 to 515) (P<0.0001 for both comparisons). Within these age bands, no significant difference in geometric mean titres of bactericidal antibody between recipients of the different serogroup C meningococcal vaccines was seen. More than 70% of participants had received a vaccine from one manufacturer; in this cohort, geometric mean titres were higher in those immunised at aged 10 years or above than in those immunised before the age of 10. CONCLUSIONS: Higher concentrations of bactericidal antibody are seen five years after immunisation with serogroup C meningococcal vaccine at age 10 years or above than in younger age groups, possibly owing to immunological maturation. This provides support for adolescent immunisation programmes to generate sustained protection against serogroup C meningococcal disease not only for the vaccine recipients but also, through the maintenance of herd immunity, for younger children.
OBJECTIVE: To determine the persistence of bactericidal antibody titres following immunisation with serogroup C meningococcal glycoconjugate vaccine at age 6-15 years in order to examine changes in persistence of antibodies with age. DESIGN: Observational study. SETTING: Secondary and tertiary educational institutions in the United Kingdom. PARTICIPANTS: Healthy adolescents aged 11-20 years previously immunised between 6 and 15 years of age with one of the three serogroup C meningococcal vaccines. INTERVENTION: Serum obtained by venepuncture. MAIN OUTCOME MEASURES: Percentage of participants with (rabbit complement) serum bactericidal antibody titres of at least 1:8; geometric mean titres of serogroup C meningococcal serum bactericidal antibody. RESULTS: Five years after immunisation, 84.1% (95% confidence interval 81.6% to 86.3%) of 987 participants had a bactericidal antibody titre of at least 1:8. Geometric mean titres of bactericidal antibody were significantly lower in 11-13 year olds (147, 95% confidence interval 115 to 188) than in 14-16 year olds (300, 237 to 380) and 17-20 year olds (360, 252 to 515) (P<0.0001 for both comparisons). Within these age bands, no significant difference in geometric mean titres of bactericidal antibody between recipients of the different serogroup C meningococcal vaccines was seen. More than 70% of participants had received a vaccine from one manufacturer; in this cohort, geometric mean titres were higher in those immunised at aged 10 years or above than in those immunised before the age of 10. CONCLUSIONS: Higher concentrations of bactericidal antibody are seen five years after immunisation with serogroup C meningococcal vaccine at age 10 years or above than in younger age groups, possibly owing to immunological maturation. This provides support for adolescent immunisation programmes to generate sustained protection against serogroup C meningococcal disease not only for the vaccine recipients but also, through the maintenance of herd immunity, for younger children.
Authors: Cressida Auckland; Stephen Gray; Ray Borrow; Nick Andrews; David Goldblatt; Mary Ramsay; Elizabeth Miller Journal: J Infect Dis Date: 2006-11-08 Impact factor: 5.226
Authors: Ray Borrow; David Goldblatt; Nick Andrews; Jo Southern; Lindsey Ashton; Sarah Deane; Rhonwen Morris; Keith Cartwright; Elizabeth Miller Journal: J Infect Dis Date: 2002-10-08 Impact factor: 5.226
Authors: O Castillo de Febres; M Chacon de Petrola; L Casanova de Escalona; O Naveda; M Naveda; M Estopinan; G Bordones; B Zambrano; A Garcia; R Dumas Journal: Vaccine Date: 1999-11-12 Impact factor: 3.641
Authors: Moya Burrage; Andrew Robinson; Ray Borrow; Nick Andrews; Joanna Southern; Jamie Findlow; Sarah Martin; Carol Thornton; David Goldblatt; Michael Corbel; Dorothea Sesardic; Keith Cartwight; Peter Richmond; Elizabeth Miller Journal: Infect Immun Date: 2002-09 Impact factor: 3.441
Authors: Jodie McVernon; Jenny Maclennan; Jim Buttery; Philipp Oster; Lisa Danzig; E Richard Moxon Journal: Pediatr Infect Dis J Date: 2002-08 Impact factor: 2.129
Authors: Caroline L Trotter; Ray Borrow; Jamie Findlow; Ann Holland; Sarah Frankland; Nick J Andrews; Elizabeth Miller Journal: Clin Vaccine Immunol Date: 2008-09-30
Authors: Susanne P Stoof; Mariëtte B van Ravenhorst; Debbie M van Rooijen; Richarda M de Voer; Fiona R M van der Klis; Greet J Boland; Elisabeth A M Sanders; Guy A M Berbers; Peter F Teunis Journal: Clin Vaccine Immunol Date: 2017-02-06
Authors: Maria Grazia Pascucci; Valentina Di Gregori; Gabriella Frasca; Paola Rucci; Alba Carola Finarelli; Laura Moschella; Bianca Maria Borrini; Francesca Cavrini; Giovanna Liguori; Vittorio Sambri; Paolo Bonanni; Maria Pia Fantini Journal: Hum Vaccin Immunother Date: 2013-12-30 Impact factor: 3.452
Authors: Anoop S Pulickal; Samir Gautam; Elizabeth A Clutterbuck; Stephen Thorson; Buddha Basynat; Neelam Adhikari; Katherine Makepeace; Sjoerd Rijpkema; Ray Borrow; Jeremy J Farrar; Andrew J Pollard Journal: Clin Vaccine Immunol Date: 2009-08-26